SCHEMBL901639

SCHEMBL901639

CCOC(=O)CCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.61
CYP4A11 Q02928 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.57
TSHR P16473 2/20 0.57
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
PYGL P06737 1/20 0.50
CDK8 P49336 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
CYP4Z1 Q86W10 1/20 0.49
PDE3B Q13370 1/20 0.47
PDE3A Q14432 1/20 0.47
P2RY12 Q9H244 1/20 0.47
PDPK1 O15530 1/20 0.47
APP P05067 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3734531 0.88 CYP4F2 (0.58) CYP4F2CYP4A11SMN1; SMN2TSHRCYP4Z1
SCHEMBL901787 0.86 CYP4F2 (0.56) CYP4F2CYP4A11SMN1; SMN2TSHRALDH1A1
SCHEMBL12723403 0.86 CYP4F2 (0.56) CYP4F2CYP4A11SMN1; SMN2TSHRALDH1A1
SCHEMBL901163 0.86 CYP4F2 (0.56) CYP4F2CYP4A11SMN1; SMN2TSHRALDH1A1
SCHEMBL3928804 0.86 CYP4F2 (0.56) CYP4F2CYP4A11SMN1; SMN2TSHRALDH1A1
SCHEMBL31511763 0.86 CYP4F2 (0.56) CYP4F2CYP4A11SMN1; SMN2TSHRALDH1A1
SCHEMBL22000638 0.85 CYP4F2 (0.55) CYP4F2CYP4A11SMN1; SMN2ALDH1A1CDK8
SCHEMBL9444904 0.84 SYK (0.49) CYP4F2CYP4A11SMN1; SMN2TSHRPDE3B
SCHEMBL8560753 0.84 SMN1; SMN2 (0.55) CYP4F2CYP4A11SMN1; SMN2TSHRALDH1A1
SCHEMBL31441301 0.83 TSHR (0.60) CYP4F2CYP4A11SMN1; SMN2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
CN-103328479-A 7-hydroxy-pyrazolo [1,5-a ] pyrimidine compounds and their use as CCR2 receptor antagonists PROXIMAGEN LTD 2013-09-25 CN disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed
US-4218452-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1980-08-19 US disclosed
US-4159329-A BLOCKING AGENTS, ANTAGONISTS, ANTIHISTAMINES SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) 1979-06-26 US disclosed
US-4145546-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 CYP4F2 1184/4885CYP4A11 639/4885SMN1; SMN2 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.